ASCO® 2023 Insights: "KRd vs. Elotuzumab + KRd in Transplant-Eligible Pts With NDMM - Post-Induction Response and MRD Results From an Open-Label Randomized Phase 3 Study"

104 views
June 15, 2023
Comments 0
Login to view comments. Click here to Login